Examination of antimicrobial activity of selected non-antibiotic products

Abstract

A variety of pharmaceutical preparations, which are applied in the management of non-infectious diseases, have shown in vitro some antimicrobial activity. These drugs are called "non-antibiotics". So far, a lot of attention has been focused on phenothiazines, thioxanthenes and other agents with affinities to cellular transport systems or agents showing other inhibition mechanism. Several authors confirmed that some nonantibiotics are "helper compounds", which enhance the in vitro activity of certain antibiotics against specific bacteria (ex. omeprazole and nizatidine enhance the effect of metronidazole on Helicobacter pylori). The aim of this study was to detect and characterise the antimicrobial activity of non-antibiotic drugs , selected from the pharmaceutical products analysed during the state control performed in National Medicines Institute in Warsaw. Over 100 pharmaceutical preparations were randomly chosen from different groups of drugs. The surveillance study was performed on standard ATCC microbial strains used for drug control: The MIC values of active substances of above drugs were evaluated. The broad spectrum of activity was found in case of clomethiazole which inhibited growth of all tested strains ( MIC: 1.6 -3.2 mg/ml ). All tested bacterial strains were inhibited by hydroxycarbamide (MIC: 0.8 -1.6 mg/ml). The high activity against Gram-positive strains was found for drotaverine and rupatadine (MIC: 0.4 mg/ml). Mould strain A. brasiliensis was inhibited by ibandronic acid (MIC 3.2 mg/ml), clomethiazole (MIC 1.6 mg/ml) and cyclosporine (MIC 0.8 mg/ml). Moreover ibandronic acid was active against P. aeruginosa in relatively low concentration (MIC: 0.2 mg/ml). In case of antiviral tablets Lazivir (two active substance: lamivudine and zidovudine) only zidovudine inhibited growth of E. coli in very low concentration 0.00125 mg/ml whereas lamivudine to concentration 1.6 mg/ml did not show any inhibition towards tested strains. The antimicrobial activity of the drugs emphasize a necessity of neutralization of their activity during microbial purity assays of pharmaceutical products.PeerJ Preprints | https://doi.org/10.7287/peerj.preprints.1807v1 | CC-BY 4.0 Open Access | rec:

Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE−/− mice

“…4 ). The mechanism behind the effects of telmisartan on microbiota can only be speculated upon but could reflect the selective antimicrobial potential previously associated with telmisartan (Kruszewska et al 2002 ). While the causal relationship to atherosclerosis inhibition is not known, these crude profiles of the predominant endogenous gut bacteria indicate that further studies with more thorough methodology are warranted to investigate whether the beneficial effects of VSL#3 were mediated via compositional modulation of gut microbiota.…”

A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile

“…One report showed minimum inhibitory concentrations (MIC) in the range of 5-10,000 lg/ml for gram-positive and gram-negative organisms as part of a quality control report. 21 A conference abstract reported alendronate MIC of 100-800 mg/L for a panel of gram-negative organisms. 22 In a periodontitis rat model, it was also reported that sodium alendronate inhibited growth of Fusobacterium nucleatum and Peptostreptococcus sp.…”

The Role of Gut Microbiome in Autoimmune Uveitis

“…MTX is a structural analog of folic acid that can competitively inhibit the binding of dihydrofolic acid to the enzyme dihydrofolate reductase, thereby interfering with purine and pyrimidine metabolism and therefore inhibiting DNA and RNA synthesis, DNA repair, and cell division. MTX has been found to be bacteriostatic in vitro against Staphylococcus aureus (but not against E. coli and Pseudomonas aeruginosa ) [51].…”